8 completed, 3 recruiting, 3 terminated, 2 active not recruiting. 17 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 8, Recruiting 3, Terminated 3, Active not recruiting 2, Not yet recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Completed 1 |
Follow Multiple System Atrophy: new trials by email Literature Review of Multiple System Atrophy trials Research Report on Multiple System Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P) ONO-2808, Placebo - Multiple System Atrophy, Parkinson Variant | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 486 | 2027-01-01 | 2026-09-17 |
| Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy 3-N-butylphthalide - Multiple System Atrophy | Phase 2 / Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 150 | 2026-08-27 | 2026-10-16 |
| MSA-01 in Multiple System Atrophy MSA-01, Placebo - Multiple System Atrophy (MSA) | Phase 3 | Recruiting | Tokyo University | 140 | 2026-02-09 | 2026-03-04 |
| A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) Amlenetug, Placebo - Multiple System Atrophy | Phase 3 | Active not recruiting | H. Lundbeck A/S | 401 | 2024-12-03 | 2026-10-14 |
| [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD [18F]-MFBG PET CT, [18F]-FE-PE2I PET CT or PET MRI, [123I]-MIBG SPECT CT - Parkinson Disease, Dementia With Lewy Bodies | Phase 2 / Phase 3 | Recruiting | prof. dr. Koen Van Laere | 113 | 2024-01-19 | 2025-02-06 |
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy Ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | Phase 3 | Active not recruiting | Theravance Biopharma | 102 | 2023-06-27 | 2025-09-05 |
| A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD) | Phase 3 | Completed | GE Healthcare | 172 | 2020-06-28 | 2023-10-16 |
| Study of BHV-3241 in Participants With Multiple System Atrophy Verdiperstat, Placebo - Multiple System Atrophy | Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 421 | 2019-07-29 | 2023-09-29 |
| Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy Tllsh2910, Placebo - Ataxia, Cerebellar, Multiple System Atrophy | Phase 3 | Terminated | National Taiwan University Hospital | 18 | 2019-04-02 | 2023-04-07 |
| Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Completed | Theravance Biopharma | 195 | 2019-01-24 | 2022-09-14 |
| Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA L-Threo DOPS, placebo - Multiple System Atrophy | Phase 2 / Phase 3 | Completed | University Hospital, Toulouse | 107 | 2014-01-21 | 2026-04-08 |
| Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach EGCG as putative neuroprotective agent, Placebo - Multiple System Atrophy | Phase 3 | Completed | Dr. Johannes Levin | 92 | 2014-01-01 | 2024-03-12 |
| Study of Rifampicin in Multiple System Atrophy Rifampicin, placebo - Multiple System Atrophy | Phase 3 | Terminated | Phillip Low | 100 | 2011-03-01 | 2014-03-28 |
| A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Placebo, Droxidopa - Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 263 | 2008-09-01 | 2014-05-16 |
| Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Droxidopa, Placebo - Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 103 | 2008-01-01 | 2014-05-16 |
| Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Placebo, Droxidopa - Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 181 | 2008-01-01 | 2014-05-20 |
| Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) Riluzole - Multiple System Atrophy, Progressive Supranuclear Palsy | Phase 3 | Terminated | King's College London | 800 | 2000-04-01 | 2005-12-15 |
Hypotension, Orthostatic (4) · Parkinson Disease (4) · Parkinsonian Disorders (4) · Pure Autonomic Failure (4) · dopamine beta hydroxylase deficiency (3) · Movement Disorders (2) · Shy-Drager Syndrome (2) · Supranuclear Palsy, Progressive (2) · Alzheimer Disease (1) · Cerebellar Ataxia (1) · Dementia (1) · Dizziness (1) · Essential Tremor (1) · Hypotension (1)
Autonomic Nervous System Diseases (17) · Basal Ganglia Diseases (17) · Brain Diseases (17) · Central Nervous System Diseases (17) · Nervous System Diseases (17) · Primary Dysautonomias (16) · Synucleinopathies (16) · Movement Disorders (15) · Neurodegenerative Diseases (15) · Cardiovascular Diseases (7) · Vascular Diseases (7) · Hypotension (6) · Neurologic Manifestations (4) · Orthostatic Intolerance (4) · Pathological Conditions, Signs and Symptoms (4)
Droxidopa (4) · ampreloxetine (2) · 3-n-butylphthalide (1) · Injections (1) · Iodine-123 (1) · Riboflavin (1) · Rifampin (1) · Riluzole (1) · epigallocatechin gallate (1) · ioflupane (1) · isoniazid, pyrazinamide, rifampin drug combination (1)
Chelsea Therapeutics (3) · Theravance Biopharma (2) · Biohaven Pharmaceuticals, Inc. (1) · Dr. Johannes Levin (1) · GE Healthcare (1) · H. Lundbeck A/S (1) · King's College London (1) · National Taiwan University Hospital (1) · Ono Pharmaceutical Co., Ltd. (1) · Phillip Low (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Tokyo University (1) · University Hospital, Toulouse (1) · prof. dr. Koen Van Laere (1)
United States (8) · Canada (6) · Australia (5) · France (5) · Germany (5) · United Kingdom (5) · Italy (4) · New Zealand (4) · Austria (3) · Spain (3) · China (2) · Denmark (2) · Estonia (2) · Hungary (2) · Israel (2)
Phillip A Low, MD (2) · Alberto Vasquez, MD (1) · Alvin McElveen, MD (1) · Brent Goodman, MD (1) · Christopher J Mathias, MD (1) · Christopher J. Mathias, MD (1) · Chun-Hwei Tai (1) · David Robertson, MD (1) · Horacio Kaufmann Kaufmann, MD (1) · Horacio Kaufmann, MD (1) · Jiali Pu, MD (1)
PMID 27538531, PMID 28494751, PMID 19029129, PMID 19771175, PMID 21386111, PMID 21829612, PMID 24507091, PMID 25350981, PMID 31278067, PMID 34115419, PMID 40924149, PMID 41269291, PMID 42475649
2018 (1), P01NS044233 (1), U54NS065736 (1)